Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Lymphoma

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

Abstract

Antibody-dependent cellular cytotoxicity (ADCC) is one of the possible mechanisms of action of the chimeric CD20 monoclonal antibody IDEC-C2B8 (rituximab). As granulocyte-colony stimulating factor (G-CSF) greatly enhances the cytotoxicity of neutrophils in ADCC, the efficacy of rituximab might be enhanced by the addition of G-CSF. In a phase I/II clinical trial, we investigated the safety and efficacy of the combination of rituximab and G-CSF (5 μg/kg/day, administered for 3 days, starting 2 days before each infusion) in 26 relapsed low-grade lymphoma patients. Adverse events occurred in 25/26 patients and mainly consisted of (grade I/II) fever (29%) and allergic reactions (19%). In phases I and II (375 mg/m2 rituximab+G-CSF), 19 patients were evaluable for efficacy. The response rate was 42% (8/19; 95% CI 20–67%), with 16% (3/19) complete remissions and 26% (5/19) partial remissions. The median duration of response was 18 months, the median time to progression was 24 months. We conclude that the combination of rituximab and G-CSF is well tolerated. Although the overall response rate seems comparable to that reported for rituximab monotherapy, remission duration in this pilot phase II study is remarkably long. Randomized comparison with rituximab monotherapy should substantiate this promising finding.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188–2195.

    CAS  PubMed  Google Scholar 

  2. McLaughlin P, Grillo-López A, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

    Article  CAS  PubMed  Google Scholar 

  3. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135–3143.

    Article  CAS  PubMed  Google Scholar 

  4. Hainsworth JD, Litchy S, Burris HA, Scullin Jr DC, Corso SW, Yardley DA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261–4267.

    Article  CAS  PubMed  Google Scholar 

  5. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445.

    CAS  PubMed  Google Scholar 

  6. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908.

    CAS  PubMed  Google Scholar 

  7. Harjunpaa A, Junnikkala S, Meri S . Rituximab (Anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634–641.

    Article  CAS  PubMed  Google Scholar 

  8. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF . The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135: 973–979.

    CAS  PubMed  Google Scholar 

  9. Hofmeister JK, Cooney D, Coggeshall KM . Clustered CD20 induced apoptosis: Src-family kinase the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26: 133–143.

    Article  CAS  PubMed  Google Scholar 

  10. Shan D, Ledbetter JA, Press OW . Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644–1652.

    CAS  PubMed  Google Scholar 

  11. Shan D, Ledbetter JA, Press OW . Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673–683.

    Article  CAS  PubMed  Google Scholar 

  12. Clynes RA, Towers TL, Presta LG, Ravetch JV . Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443–446.

    Article  CAS  PubMed  Google Scholar 

  13. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754–758.

    Article  CAS  PubMed  Google Scholar 

  14. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974–1981.

    Article  CAS  PubMed  Google Scholar 

  15. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270–3278.

    Article  CAS  PubMed  Google Scholar 

  16. Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L et al. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 951–958.

    CAS  PubMed  Google Scholar 

  17. Davis TA, Maloney DG, Grillo-Lopez AJ, White CA, Williams ME, Weiner GJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000; 6: 2644–2652.

    CAS  PubMed  Google Scholar 

  18. Valerius T, Repp R, de Wit T, Berthold S, Platzer E, Kalden JR et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993; 82: 931–939.

    CAS  PubMed  Google Scholar 

  19. Kerst J, de Haas M, van der Schoot C, Slaper-Cortenbach I, Kleijer M, von dem Borne A et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 1993; 82: 3265–3272.

    CAS  PubMed  Google Scholar 

  20. Elsasser D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996; 87: 3803–3812.

    CAS  PubMed  Google Scholar 

  21. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991; 78: 885–889.

    CAS  PubMed  Google Scholar 

  22. IDEC Pharmaceuticals Corporation. Investigational Drug Brochure Rituximab (RituxanTM, Mab Thera, IDEC-C2B8), 4th edn. San Diego, CA, USA: IDEC Pharmaceuticals Corporation, 1997.

  23. Nuijens JH, Abbink JJ, Wachtfogel YT, Colman RW, Eerenberg AJ, Dors D et al. Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992; 119: 159–168.

    CAS  PubMed  Google Scholar 

  24. de Haas M, Kerst JM, van der Schoot C, Calafat J, Hack CE, Nuijens JH et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994; 84: 3885–3894.

    CAS  PubMed  Google Scholar 

  25. Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000; 109: 81–88.

    Article  CAS  PubMed  Google Scholar 

  26. Lieschke GJ, Burgess AW . Granulocyte colony-stimulating factor and granulocyte–macrophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28–35.

    Article  CAS  PubMed  Google Scholar 

  27. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266–3274.

    Article  CAS  PubMed  Google Scholar 

  28. van der Kolk LE, de Haas M, Grillo-Lopez AJ, Baars JW, van Oers MH . Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 2002; 16: 693–699.

    Article  CAS  PubMed  Google Scholar 

  29. Weng K-W, Levy R . Analysis of IgG Fc Receptor FcgRIIIa polymorphism in relapsed follicular non-hodgkin's lymphoma patients treated with rituximab [abstract]. Blood 2002; 100: 1368a.

    Google Scholar 

  30. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466.

    CAS  PubMed  Google Scholar 

  31. Leavey PJ, Sellins KS, Thurman G, Elzi D, Hiester A, Silliman CC et al. In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophil functions measured in vitro. Blood 1998; 92: 4366–4374.

    CAS  PubMed  Google Scholar 

  32. Price TH, Chatta GS, Dale DC . Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88: 335–340.

    CAS  PubMed  Google Scholar 

  33. Hoglund M, Hakansson L, Venge P . Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers. Eur J Haematol 1997; 58: 195–202.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Kolk, L., Grillo-López, A., Baars, J. et al. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 17, 1658–1664 (2003). https://doi.org/10.1038/sj.leu.2402995

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402995

Keywords

This article is cited by

Search

Quick links